[1] HEITMAN J,MOVVA N R,HALL M N.Targets for cell cycle arrest by the immunosuppressant rapamycin in yesar[J].Scinece,1991,253(5022):905-909.
[2] HAY N,SONENBERG N.Upstream and downstream of mTOR[J].Genes Dev,2004,18(16):1926-1945.
[3] FOSTER K G,FINGAR D C.Mammalian target of rapamycin(mTOR):conducting the cellular singnaling symphony[J].Biol Chem,2010,285(19):14071-14077.
[4] WATANABE R,WEI L,HUANG J.MTOR signaling.function,novel inhibit-tors,and therapeutic targets[J].Nucl Med,2011,52(4):479-500.
[5] CHOUEIRI M,MACK P.The role mTOR lnhibitors and PI3K pathway blockade in RCC[J].Springer,2012,4:209-223.
[6] PETERSON T R,LAPLANTE M,THOREEN C C,et al.DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival[J].Cell,2009,137(5):873-886.
[7] JACINTO E,LOEWITH R,SCHMIDT A,et al.Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive[J].Nat Cell Biol,2004,6(11):1122-1128.
[8] WANG Y,WANG X Y,SUBJECK J R,et al.Temsirolimus,an mTOR inhibitor,enhances anti-tumour effects of heat shock protein cancer vaccines[J].Br J Cancer,2011,104(4):643-652.
[9] TAKAKO C,JUN Z.Hideyuki LST8 level controls basal p70S6 kinase and Akt phosphorylations,and mTORC1 and mTORC2 negatively regulate each other by competing for association with LST8[J].Obes Res Clin Pract,2011,6(3):215-224.
[10] SARBASSOV D D,ALI S M,KIM D H,et al.Rictor,a novel binding partner of mTOR,defines a rapamycin-insensitive and raptor- independent pathway that regulates the cytoskeleton[J].Curr Biol,2004,14(14):1296-1302.
[11] VIGNOT S,FAIVRE S,AGUIRRE D,et al.mTOR targeted therapy of cancer with rapamycin derivatives[J].Ann Oncol,2005,16(4):525-537.
[12] VINCENT W,ERIC P,ADRIENNE L,et al.PTEN and NF1 inactivation in schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors[J].Cancer Res,2012,72:3405-3413.
[13] RUTTER G A,SILVA-XAVIER G D,LECLERC I.Roles of 5'-AMP activated protein kinase(AMPK)in mammalian glucose homoeostasis[J].Biochem J,2003,375(1):1-16.
[14] INOKI K,ZHU T,GUAN K L.TSC2 mediates cellular energy response to control cell growth and survival[J].Cell,2003,115(5):577-590.
[15] CHENG S W,FRYER L G,CARLING D,et al.Thr2446 is a novel mammalian target of rapamycin(mTOR) phosphofylation site regulated by nutrient status[J].J Biol Chem,2004,279(16):15719-15722.
[16] NOWAK P,COLE D C,BROOIJMANS N,et al.Discovery of potent and selective inhibitors of the mammalian target of rapamycin(mTOR) kinase[J].Med Chem,2009,52(22):7081-7089.
[17] ZHANG Y J,DAI Q,SUN D F,et al.mTOR signaling pathway is a target for the treatment of colorectal cancer[J].Ann Surg Oncol,2009,16(9):2617-2628.
[18] WANG X M,PROUND C G.The mTOR pathway in the control of protein synthesis[J].Physiology,2006,21(6):362-369.
[19] TENESA A,DUNLOP M G.New insights into the aetiology of colorectal cancer form genomewide association studies[J].Nat Rev Genet,2009,l0(6):353-358.
[20] GUSTIN J P,KARAKAS B,WEISS M B,et al.Knockin of mutant PIK3CA activates multiple oncogenic pathways[J].Proc Natl Acad Sci USA,2009,106(8):2835-2840.
[21] JOHNSON S M,GULHATI P,RAMPY B A,et al.Novel Expression patterns of PI3K/AKT/mTOR signaling pathway components in colorectal cancer [J].J Am Coll Surg,2010,210(5):767-778.
[22] SLATTERY M L,HERRICK J S,LUNDGREEN A,et al.Genetic variation in a metabolic signaling pathway and,colon,and,rectal,risk:Mtor,PTEN,STK11,RPKAA1,PRKAG2,TSC1,PI3K.and,Aktl[J].Carcinogenesis,2010,80(5):550-560.
[23] HYUN-SOO K,GOU-YOUNG K,SUNG-JIG L,et al.Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma[J].Pathobiology,2012,79(2):84-93.
[24] TSANG C K,QI H,LIU L F,et al.Targeting mammalian target of rampamycin(mTOR) for health and diseases[J].Discov Today,2007,12(3-4):112-124.
[25] 张燕捷,房静远,矫强,等.DNA甲基化酶抑制剂与雷帕霉素对人结直肠癌细胞周期及mTOR信号转导通路的联合调控[J].中华消化内镜杂志,2007,24(5):360-364.
[26] GULHATI P,CAI Q,LI J,et al.Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer[J].Clin Cancer Res,2009,15(23):7207-7216.
[27] JOHNSON S M,GULHATI P,ARRIETA I,et al.Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling[J].Anticancer Res,2009,29(8):3185-3190.
[28] DENG L,ZHOU J F,SELLERS R S,et al.A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin- dependent hyperproliferation of colonic epithelium to inflammation- associated tumorigenesis[J].Pathol,2010,176(2):952-967.
[29] LOPEZ-KNOWLES E,OTOOLE S A,MCNEIL C M,et al.P13K pathway activation in breast caner is associated with the basal-like phenotype and cancer-specific mortality[J].Int J Cancer,2010,126(5):1121-1131.
[30] HUYNH H.Molecularly targeted therapy in hepatocellular carcinoma[J].Biochem Pharmacol,2010,31(9):1604-1611.
[31] DOWLING R J,TOPISIROVIC I,ALAIN T,et al.mTORC1-mediated cell proliferation,but not cell growth,controlled by the 4E-BPs[J].Science,2010,328(5982):1172-1176.
[32] GUSTIN J P,KARAKAS B,WEISS M B,et al.Knockin of mutant PIK3CA activates multiple oncogenic pathways[J].Proc Natl Acad Sci USA,2009,106(8):2835-2840.
[33] 段思佳,曾庆黎,周凯,等.利用组织芯片研究VEGF-C和MMP-9在大肠癌中的表达及其意义[J].中国普通外科杂志,2012(4):427-431. |
